


Bae SI, Cheriyyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. *Oncogene.* 2008 Jan 17;27(4):490-498.


Campbell SC. Editorial comment [Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy]. J Urol. 2008 Feb;179(2):472.


Davis MP, Angst M. In reply [Opioid-induced hyperalgesia may be more frequent than previously thought]. J Clin Oncol. 2008 Mar 20;26(9):1565.

Davis MP. Cancer constipation: are opioids really the culprit? Support Care Cancer. 2008 May;16(5):427-429.


Davis MP, Kirkova J. Lifting symptom burden-how far off the ground are we? Support Care Cancer. 2008 Jul;16(7):757-761.


Gibson SE, Schade AE, Szpurka H, Bak B, Maciejewski JP, Hsi ED. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F. *Hum Pathol.* 2008 Jul;39(7):1111-1114.


Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran WJr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S,


Klein EA. Editorial comment [High anterior release of the levator fascia improves sexual function following open radical retropubic prostatectomy]. *J Urol.* 2008 Dec;180(6):2564.


Raghavan D, Klein EA. Prostate cancer: moving forward by reinventing the wheel...but this time it is round. *J Clin Oncol.* 2008 Oct 1;26(28):4535-4536.


Rini BI. Editorial comment [Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma]. *J Urol.* 2008 Sep;180(3):878.


Whole Books and Monographic Serials


**Book Chapters**


